Cynomolgus CLEC12A / MICL / CLL-1 Protein, His Tag

Cat. No. / Size
Price
Availability
Qty
CLA-C5246-100ug
$360.00
In Stock - Delivery in 1-2 business days
CLA-C5246-1mg (250ug X 4)
$2,615.00
In Stock - Delivery in 1-2 business days
CLA-C5246
Sub-Total :
$ 0
Customize Product Request Quote
Contact Us
Contact Us
Sub-Total:
$ 0
  • Product Details
  • Performance Data
  • Reviews & Citations
  • Important Statement
  • Resources
Synonyms

CLEC12A, MICL, CLL-1, CLL1, DCAL2, DCAL-2, CD371

Source

Cynomolgus CLEC12A, His Tag (CLA-C5246) is expressed from human 293 cells (HEK293). It contains AA His 32 - Ala 232 (Accession # A0A2K5WXQ6-1).

Predicted N-terminus: His

Molecular Characterization

This protein carries a polyhistidine tag at the N-terminus.

The protein has a calculated MW of 25.5 kDa. The protein migrates as 34-46 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin

Less than 1.0 EU per μg by the LAL method / rFC method.

Purity

>90% as determined by SDS-PAGE.

Formulation

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Shipping and Storage

This product is shipped at ambient temperature.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:
  • -20°C to -70°C for 12 months in lyophilized state;
  • -70°C for 3 months under sterile conditions after reconstitution.

Background

CLEC12A (C-type lectin domain family 12 member A) is also known as CLL1, DCAL2, MICL. Clec12a is an inhibitory receptor for uric acid crystals that regulates inflammation in response to cell death. Cell surface receptor that modulates signaling cascades and mediates tyrosine phosphorylation of target MAP kinases. Evidence of distinct disease propagating stem cells in myelodysplastic syndrome (MDS) has emerged in recent years. The role of CLEC12A in MDS, however, remains to be elucidated. Furthermore, CLEC12A has been proposed as a promising marker of leukaemic stem cells in AML.